Partnering Strategy and Capabilities

CarnaBio’s strategy is to partner with pharmaceutical and biotechnology companies at early stage programs, the IND candidate or early clinical stage.

CarnaBio’s powerful kinase drug discovery platform starts with the screening of its lead-like compound library, followed by the use of a kinase profiling panel to select lead candidates and drive chemistry optimization to identify highly selective drug candidates.
The company has established an ensemble library consists of kinase-focused and diverse-set compounds that maximizes a success rate of screening, over 300 HTS-ready kinase assays, and a strategic synthetic and medicinal chemistry team. QuickScout™ , the powerful kinase panel, is particularly amenable to the design of highly selective inhibitors of kinase targets.

For further information on CarnaBio’s approach to partnering and current opportunities please contact;

Masaaki Sawa, Ph.D. Director of Medicinal Chemistry